vs
Side-by-side financial comparison of Hologic (HOLX) and NATIONAL FUEL GAS CO (NFG). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $425.9M, roughly 2.5× NATIONAL FUEL GAS CO). NATIONAL FUEL GAS CO runs the higher net margin — 35.7% vs 17.1%, a 18.6% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs 1.7%). Over the past eight quarters, NATIONAL FUEL GAS CO's revenue compounded faster (12.1% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
National Fuel Gas Company is a diversified energy company with $6.2 billion in assets distributed among the following five operating segments: Exploration and Production, Pipeline and Storage, Gathering, Utility, and Energy Marketing. National Fuel Gas was incorporated in 1902 and is based in Williamsville, New York.
HOLX vs NFG — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $425.9M |
| Net Profit | $179.1M | $152.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 81.5% |
| Net Margin | 17.1% | 35.7% |
| Revenue YoY | 2.5% | 1.7% |
| Net Profit YoY | -10.9% | — |
| EPS (diluted) | $0.79 | $1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $425.9M | ||
| Q4 25 | $1.0B | $637.9M | ||
| Q3 25 | $1.0B | $443.1M | ||
| Q2 25 | $1.0B | $527.4M | ||
| Q1 25 | $1.0B | $734.8M | ||
| Q4 24 | $1.0B | $513.8M | ||
| Q3 24 | $988.0M | $310.0M | ||
| Q2 24 | $1.0B | $338.6M |
| Q1 26 | — | $152.0M | ||
| Q4 25 | $179.1M | $181.6M | ||
| Q3 25 | $187.2M | $107.3M | ||
| Q2 25 | $194.9M | $149.8M | ||
| Q1 25 | $-17.4M | $216.4M | ||
| Q4 24 | $201.0M | $45.0M | ||
| Q3 24 | $178.6M | $-167.6M | ||
| Q2 24 | $194.5M | $-54.2M |
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | 86.6% | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | 94.7% | ||
| Q1 25 | 37.5% | 81.6% | ||
| Q4 24 | 56.8% | 87.3% | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | 98.5% |
| Q1 26 | — | 81.5% | ||
| Q4 25 | 22.6% | 43.3% | ||
| Q3 25 | 22.6% | 40.6% | ||
| Q2 25 | 24.9% | 43.7% | ||
| Q1 25 | -0.7% | 43.2% | ||
| Q4 24 | 22.5% | 16.8% | ||
| Q3 24 | 23.3% | -63.4% | ||
| Q2 24 | 24.1% | -15.2% |
| Q1 26 | — | 35.7% | ||
| Q4 25 | 17.1% | 28.5% | ||
| Q3 25 | 17.8% | 24.2% | ||
| Q2 25 | 19.0% | 28.4% | ||
| Q1 25 | -1.7% | 29.4% | ||
| Q4 24 | 19.7% | 8.8% | ||
| Q3 24 | 18.1% | -54.1% | ||
| Q2 24 | 19.2% | -16.0% |
| Q1 26 | — | $1.59 | ||
| Q4 25 | $0.79 | $1.98 | ||
| Q3 25 | $0.84 | $1.18 | ||
| Q2 25 | $0.86 | $1.64 | ||
| Q1 25 | $-0.08 | $2.37 | ||
| Q4 24 | $0.87 | $0.49 | ||
| Q3 24 | $0.75 | $-1.81 | ||
| Q2 24 | $0.82 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | $2.5B | $300.0M |
| Stockholders' EquityBook value | $5.2B | — |
| Total Assets | $9.2B | $9.1B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $271.4M | ||
| Q3 25 | $2.2B | $43.2M | ||
| Q2 25 | $1.9B | $39.3M | ||
| Q1 25 | $1.6B | $40.0M | ||
| Q4 24 | $2.0B | $48.7M | ||
| Q3 24 | $2.3B | $38.2M | ||
| Q2 24 | $2.4B | $81.4M |
| Q1 26 | — | $300.0M | ||
| Q4 25 | $2.5B | $2.7B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.5B | $2.7B | ||
| Q1 25 | $2.5B | $2.7B | ||
| Q4 24 | $2.5B | $2.7B | ||
| Q3 24 | $2.5B | $2.7B | ||
| Q2 24 | $2.5B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | $5.2B | $3.6B | ||
| Q3 25 | $5.0B | $3.1B | ||
| Q2 25 | $4.8B | $3.0B | ||
| Q1 25 | $4.6B | $2.8B | ||
| Q4 24 | $4.8B | $-76.2M | ||
| Q3 24 | $5.1B | $-15.5M | ||
| Q2 24 | $5.0B | $5.0M |
| Q1 26 | — | $9.1B | ||
| Q4 25 | $9.2B | $9.2B | ||
| Q3 25 | $9.0B | $8.7B | ||
| Q2 25 | $8.8B | $8.4B | ||
| Q1 25 | $8.5B | $8.5B | ||
| Q4 24 | $8.7B | $8.3B | ||
| Q3 24 | $9.2B | $8.3B | ||
| Q2 24 | $8.9B | $8.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | 0.75× | ||
| Q3 25 | 0.50× | 0.87× | ||
| Q2 25 | 0.52× | 0.90× | ||
| Q1 25 | 0.55× | 0.99× | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | 532.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $657.3M |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | 117.0% |
| Cash ConversionOCF / Net Profit | 1.28× | 4.32× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $657.3M | ||
| Q4 25 | $229.9M | $274.9M | ||
| Q3 25 | $355.1M | $237.8M | ||
| Q2 25 | $343.3M | $388.4M | ||
| Q1 25 | $169.4M | $253.8M | ||
| Q4 24 | $189.3M | $220.1M | ||
| Q3 24 | $367.0M | $197.9M | ||
| Q2 24 | $405.8M | $281.8M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $-2.7M | ||
| Q3 25 | $341.4M | $-47.8M | ||
| Q2 25 | $330.5M | $195.3M | ||
| Q1 25 | $153.9M | $59.9M | ||
| Q4 24 | $172.5M | $-20.3M | ||
| Q3 24 | $350.6M | $-49.1M | ||
| Q2 24 | $385.3M | $79.5M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | -0.4% | ||
| Q3 25 | 32.5% | -10.8% | ||
| Q2 25 | 32.3% | 37.0% | ||
| Q1 25 | 15.3% | 8.2% | ||
| Q4 24 | 16.9% | -4.0% | ||
| Q3 24 | 35.5% | -15.8% | ||
| Q2 24 | 38.1% | 23.5% |
| Q1 26 | — | 117.0% | ||
| Q4 25 | 1.4% | 43.5% | ||
| Q3 25 | 1.3% | 64.4% | ||
| Q2 25 | 1.3% | 36.6% | ||
| Q1 25 | 1.5% | 26.4% | ||
| Q4 24 | 1.6% | 46.8% | ||
| Q3 24 | 1.7% | 79.7% | ||
| Q2 24 | 2.0% | 59.7% |
| Q1 26 | — | 4.32× | ||
| Q4 25 | 1.28× | 1.51× | ||
| Q3 25 | 1.90× | 2.21× | ||
| Q2 25 | 1.76× | 2.59× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | 0.94× | 4.89× | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
NFG
| Revenues from External Customers | $425.8M | 100% |
| Intersegment Revenues | $126.0K | 0% |
